Progrediente Aortenklappenstenose – sind effektive, phänotypbasierte, pharmakologische Strategien endlich in Sicht?

Die Aortenklappenstenose ist eine aktiv voranschreitende Erkrankung, die unterschiedliche Verlaufsformen aufweist. Abgesehen von etablierten und innovativen Klappenersatzverfahren gibt es bislang keine effektive pharmakologische Therapie, die der Entstehung oder dem Progress der Aortenstenose zielgerichtet entgegenwirkt. In diesem Beitrag werden zugrunde liegende Pathomechanismen und mögliche zukünftige therapeutische Ziele näher beleuchtet.

Schlüsselwörter

Aortenklappenstenose - Progress - Echokardiografie - Inflammation - Fibrose - Kalzifikation - Ossifikation - Monozyten - Plättchen

• Literatur

• 1 Yutzey KE, Demer LL, Body SC. et al. Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol 2014; 34: 2387-2393
• 2 Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316-3326
• 3 Makkar RR, Thourani VH, Mack MJ. et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med 2020; 382: 799-809
• 4 Lindroos M, Kupari M, Valvanne J. et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994; 15: 865-870
• 5 Otto CM, Kuusisto J, Reichenbach DD. et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-853
• 6 Otto CM, Nishimura RA, Bonow RO. et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143: e72-e227
• 7 Vahanian A, Beyersdorf F, Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021; 60: 727-800
• 8 Dweck MR, Khaw HJ, Sng GK. et al. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation?. Eur Heart J 2013; 34: 1567-1574
• 9 Aikawa E, Libby P. A Rock and a Hard Place: Chiseling Away at the Multiple Mechanisms of Aortic Stenosis. Circulation 2017; 135: 1951-1955
• 10 Goody PR, Hosen MR, Christmann D. et al. Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets. Arterioscler Thromb Vasc Biol 2020; 40: 885-900
• 11 Pawade TA, Newby DE. et al. Calcification in Aortic Stenosis: The Skeleton Key. J Am Coll Cardiol 2015; 66: 561-577
• 12 Raddatz MA, Madhur MS, Merryman WD. Adaptive immune cells in calcific aortic valve disease. Am J Physiol Heart Circ Physio 2019; 317: H141-H155
• 13 Bouchareb R, Boulanger MC, Tastet L. et al. Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. Eur Heart J 2019; 40: 1362-1373
• 14 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384
• 15 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67
• 16 Wirtz TH, Tillmann S, Strüßmann T. et al. Platelet-derived MIF: a novel platelet chemokine with distinct recruitment properties. Atherosclerosis 2015; 239: 1-10
• 17 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896
• 18 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422
• 19 Rutkovskiy A, Malashicheva A, Sullivan G. et al. Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification. J Am Heart Assoc 2017; 6: e006339
• 20 Goldbarg SH, Elmariah S, Miller MA. et al. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007; 50: 1205-1213
• 21 Kraler S, Blaser MC, Aikawa E. et al. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J 2022; 43: 683-697
• 22 Mohler 3rd ER, Gannon F, Reynolds C. et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522-1528
• 23 Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007; 171: 1407-1418
• 24 Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009; 135: 4-13
• 25 Hara T, Fukuda D, Tanaka K. et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242: 639-646
• 26 Kadoglou NP, Moustardas P, Katsimpoulas M. et al. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther 2012; 26: 367-374
• 27 Lee IO, Kratz MT, Schirmer SH. et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012; 343: 253-257
• 28 Zhou Q, Bea F, Preusch M. et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080
• 29 Connolly SJ, Eikelboom JW, Bosch J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 205-218
• 30 Ridker PM, Devalaraja M, Baeres FMM. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021; 397: 2060-2069
• 31 Banach M, Penson PE. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. Curr Atheroscler Rep 2021; 23: 32
• 32 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722
• 33 Sriranjan R, Zhao TX, Tarkin J. et al. Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. BMJ Open 2022; 12: e062602